| 1 |
34304352 | Drug-interaction between paclitaxel and goshajinkigan extract and its constituents. | 2022 Jan |
2 |
| 2 |
33446524 | In Vitro Evidence of Potential Interactions between CYP2C8 and Candesartan Acyl-β-D-glucuronide in the Liver. | 2021 Apr |
1 |
| 3 |
33491578 | Physicochemical characterization of paclitaxel prodrugs with cytochrome 3A4 to correlate solubility and bioavailability implementing molecular docking and simulation studies. | 2021 Jan 25 |
1 |
| 4 |
33513992 | Hyaluronic Acid-Targeted Stimuli-Sensitive Nanomicelles Co-Encapsulating Paclitaxel and Ritonavir to Overcome Multi-Drug Resistance in Metastatic Breast Cancer and Triple-Negative Breast Cancer Cells. | 2021 Jan 27 |
2 |
| 5 |
33649523 | Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients. | 2021 Aug |
4 |
| 6 |
34097831 | Carbon Monoxide Inhibits Cytochrome P450 Enzymes CYP3A4/2C8 in Human Breast Cancer Cells, Increasing Sensitivity to Paclitaxel. | 2021 Jun 24 |
5 |
| 7 |
32364081 | Paclitaxel Nanoparticles Induce Apoptosis and Regulate TXR1, CYP3A4 and CYP2C8 in Breast Cancer and Hepatoma Cells. | 2020 |
1 |
| 8 |
32505840 | Xiaoaiping injection enhances paclitaxel efficacy in ovarian cancer via pregnane X receptor and its downstream molecules. | 2020 Oct 28 |
1 |
| 9 |
30840584 | Enhanced anti-cancer activity by menthol in HepG2 cells exposed to paclitaxel and vincristine: possible involvement of CYP3A4 downregulation. | 2019 Mar 6 |
1 |
| 10 |
29054579 | Relevance of the CYP3A4*20 variant as a predictor of paclitaxel-induced neuropathy in the Spanish population. | 2018 Feb 23 |
1 |
| 11 |
29251928 | Comprehensive Synthesis of Amino Acid-Derived Thiazole Peptidomimetic Analogues to Understand the Enigmatic Drug/Substrate-Binding Site of P-Glycoprotein. | 2018 Feb 8 |
1 |
| 12 |
27599706 | Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. | 2017 Apr |
1 |
| 13 |
26910068 | In Vitro Approaches to Study Regulation of Hepatic Cytochrome P450 (CYP) 3A Expression by Paclitaxel and Rifampicin. | 2016 |
3 |
| 14 |
27572875 | Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells. | 2016 Sep |
1 |
| 15 |
27574448 | Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. | 2016 |
1 |
| 16 |
25398452 | Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. | 2015 Jan 15 |
3 |
| 17 |
25424246 | Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes. | 2015 Jun |
4 |
| 18 |
26211584 | Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer. | 2015 Jul |
1 |
| 19 |
24476576 | Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials. | 2014 Apr |
3 |
| 20 |
24637579 | Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review. | 2014 May |
1 |
| 21 |
24800949 | Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. | 2014 May 27 |
1 |
| 22 |
23090875 | P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. | 2013 May 15 |
5 |
| 23 |
23629743 | The tyrosine kinase inhibitor nilotinib selectively inhibits CYP2C8 activities in human liver microsomes. | 2013 |
2 |
| 24 |
23640974 | CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. | 2013 Jun 15 |
4 |
| 25 |
23936594 | Influence of CYP3A4 genotypes in the outcome of serous ovarian cancer patients treated with first-line chemotherapy: implication of a CYP3A4 activity profile. | 2013 |
2 |
| 26 |
22680343 | Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure. | 2012 Jul |
1 |
| 27 |
22764771 | Pharmacologic modulation strategies to reduce dose requirements of anticancer therapy while preserving clinical efficacy. | 2012 Jun |
1 |
| 28 |
20212519 | Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. | 2011 Apr |
1 |
| 29 |
21056987 | Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model. | 2011 Feb |
1 |
| 30 |
21327421 | Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. | 2011 Jul |
1 |
| 31 |
20814160 | Comparison of cytochrome P450 3A enzymes in cynomolgus monkeys and humans. | 2010 |
1 |
| 32 |
20847137 | CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. | 2010 Dec |
5 |
| 33 |
20977456 | Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. | 2010 Nov |
1 |
| 34 |
22966274 | The ABCB1 3435 T allele does not increase the risk of paclitaxel-induced neurotoxicity. | 2010 Jan |
2 |
| 35 |
18839173 | Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. | 2009 Jun |
2 |
| 36 |
19143748 | Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. | 2009 Feb |
2 |
| 37 |
17992531 | Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. | 2008 Aug |
2 |
| 38 |
18039807 | Taxane's substituents at C3' affect its regioselective metabolism: different in vitro metabolism of cephalomannine and paclitaxel. | 2008 Feb |
1 |
| 39 |
17267149 | Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. | 2007 Jun 7 |
1 |
| 40 |
17399990 | In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2). | 2007 Jun 1 |
1 |
| 41 |
17701008 | Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. | 2007 Aug |
1 |
| 42 |
17906456 | Individualized pharmacotherapy with paclitaxel. | 2007 Nov |
1 |
| 43 |
16708050 | Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans. | 2006 Jun |
1 |
| 44 |
16753005 | Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8. | 2006 Jun |
1 |
| 45 |
16890579 | Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. | 2006 Aug |
2 |
| 46 |
16904325 | In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity at CYP-450. | 2006 Dec 1 |
1 |
| 47 |
15650019 | The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. | 2005 May |
2 |
| 48 |
15655291 | Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4. | 2005 Jan |
4 |
| 49 |
15856231 | P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing. | 2005 Sep |
3 |
| 50 |
15864135 | Functional characterization of a novel polymorphism of pregnane X receptor, Q158K, in Chinese subjects. | 2005 May |
2 |